# EDGAR Filing Document

**Accession Number:** 0001463361
**File Stem:** 0001193125-25-187684
**Filing Date:** 2025-8
**Character Count:** 12474
**Document Hash:** 85db9b4687bb8758c361bcd07597ea1c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-187684.hdr.sgml**: 20250825

**ACCESSION NUMBER**: 0001193125-25-187684

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250825

**DATE AS OF CHANGE**: 20250825

**EFFECTIVENESS DATE**: 20250825

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Unity Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001463361
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264726035
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-250926
- **FILM NUMBER:** 251250953

**BUSINESS ADDRESS:**
- **STREET 1:** 285 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 416-1192

**MAIL ADDRESS:**
- **STREET 1:** 285 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cenexys, Inc.
- **DATE OF NAME CHANGE:** 20130703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Forge Inc
- **DATE OF NAME CHANGE:** 20090504

**As filed with the Securities and Exchange Commission on August 25, 2025** 

**Registration No. 333-224726** 

**Registration No. 333-230086** 

**Registration No. 333-237088** 

**Registration No. 333-237474** 

**Registration No. 333-250926** 

**Registration No. 333-254619** 

**Registration No. 333-263576** 

**Registration No. 333-270567** 

**Registration No. 333-278679** 

**Registration No. 333-285649** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224726** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230086** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237088** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237474** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-250926** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254619** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263576** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-270567** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-278679** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-285649** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

## UNITY BIOTECHNOLOGY, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **26-4726035** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification Number)** |

---

**124 Washington Street, Suite 101** 

**Foxborough, Massachusetts 02035** 

**(508) 543-1720** 

**(Address of Principal Executive Offices)** 

**Unity Biotechnology, Inc. 2013 Equity Incentive Plan** 

**Unity Biotechnology, Inc. 2018 Incentive Award Plan** 

**Unity Biotechnology, Inc. 2018 Employee Stock Purchase Plan** 

**Unity Biotechnology, Inc. 2020 Employment Inducement Incentive Award Plan** 

**(Full Title of the Plans)** 

**Craig R. Jalbert** 

**President, Secretary, and Director** 

**Unity Biotechnology, Inc.** 

**124 Washington Street, Suite 101** 

**Foxborough, Massachusetts 02035** 

**(508) 543-1720** 

**(Name and address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Erica Kassman** 

**Latham & Watkins LLP** 

**140 Scott Drive** 

**Menlo Park, CA 94025** 

**Telephone: (650) 328-4600** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

**DEREGISTRATION OF SECURITIES** 

This Post-Effective Amendment No. 1 ("<u>Post</u><u>-Effective Amendment No.</u> <u>1</u>") filed by Unity Biotechnology, Inc., a Delaware corporation (the "<u>Company</u>"), removes from registration all shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), registered under the following Registration Statements on Form S-8 (each a "<u>Registration Statement</u>" and, collectively, the "<u>Registration Statements</u>") filed with the U.S. Securities and Exchange Commission (the "<u>Commission</u>") that remain unsold thereunder:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-224726)](http://www.sec.gov/Archives/edgar/data/1463361/000119312518154668/d580573ds8.htm) , filed with the Commission on May 7, 2018, pertaining to the registration of (i) 5,293,729 shares of the Company's Common Stock
under the Company's 2013 Equity Incentive Plan and 2018 Incentive Award Plan, (ii) 3,330,530 shares of the Company's Common Stock under the Company's 2018 Incentive Award Plan, and (iii) 536,242 shares of the Company's Common
Stock under the Company's 2018 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-230086)](http://www.sec.gov/Archives/edgar/data/1463361/000156459019006399/ubx-s8.htm) , filed with the Commission on March 6, 2019, pertaining to the registration of (i) 2,125,510 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 424,143 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-237088)](http://www.sec.gov/Archives/edgar/data/1463361/000156459020010078/ubx-s8.htm) , filed with the Commission on March 11, 2020, pertaining to the registration of (i) 2,361,841 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 472,271 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-237474)](http://www.sec.gov/Archives/edgar/data/1463361/000156459020014179/ubx-s8.htm) , filed with the Commission on March 30, 2020, pertaining to the registration of 1,100,000 shares of the Company's Common Stock under
the Company's 2020 Employment Inducement Incentive Award Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-250926)](http://www.sec.gov/Archives/edgar/data/1463361/000156459020055062/ubx-s8.htm) , filed with the Commission on November 24, 2020, pertaining to the registration of 1,500,000 shares of the Company's Common Stock
under the Company's 2020 Employment Inducement Incentive Award Plan, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-254619)](http://www.sec.gov/Archives/edgar/data/1463361/000156459021014860/ubx-s8.htm) , filed with the Commission on March 23, 2021, pertaining to the registration of (i) 2,675,309 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 532,480 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-263576)](http://www.sec.gov/Archives/edgar/data/1463361/000156459022010419/ubx-s8.htm) , filed with the Commission on March 15, 2022, pertaining to the registration of (i) 3,182,965 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 629,919 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-270567)](http://www.sec.gov/Archives/edgar/data/1463361/000095017023008178/ubx-s8-20230315.htm) , filed with the Commission on March 15, 2023, pertaining to the registration of (i) 710,765 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, (ii) 142,153 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan, and (iii) 300,000 shares of the Company's Common Stock under the
Company's 2020 Employment Inducement Incentive Award Plan, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-278679)](http://www.sec.gov/Archives/edgar/data/1463361/000095017024044243/ubx-s8-20240415.htm) , filed with the Commission on April 15, 2024, pertaining to the registration of (i) 839,248 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 167,849 shares of the Company's Common Stock under the 2018 Employee Stock Purchase Plan.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement on [Form S-8 (No. 333-285649)](http://www.sec.gov/Archives/edgar/data/1463361/000095017025035572/ubx-s8-20250307.htm) , filed with the Commission on March 7, 2025, pertaining to the registration of (i) 843,260 shares of the Company's Common Stock
under the Company's 2018 Incentive Award Plan, and (ii) 168,652 shares of the Company's Common Stock under the Company's 2018 Employee Stock Purchase Plan.

As previously reported on June 27, 2025, the board of directors of the Company: (i) determined that it is in the best interests of the Company and its stakeholders that the Company be liquidated and dissolved in accordance with the Delaware General Corporation Law pursuant to a Plan of Complete Liquidation and Dissolution (the "<u>Dissolution</u>"); and (ii) approved seeking stockholder approval to proceed with the Dissolution pursuant to Delaware law at a special meeting of stockholders and, if approved by stockholders, file a Certificate of Dissolution with the Secretary of State of the State of Delaware. In connection with the foregoing, the Company has determined to terminate the offerings of securities under the Registration Statements. Accordingly, the Company is filing this Post-Effective Amendment No. 1 to terminate the effectiveness of the Registration Statements, and, in accordance with the undertakings made by the Company in the Registration Statements, to remove from registration any and all of the securities that remain unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of all such securities. Note that the numbers of securities listed above do not take into account any applicable corporate actions, such as stock splits, that may have been taken in the interim.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on August 25, 2025.

---

| | |
|:---|:---|
| **UNITY BIOTECHNOLOGY, INC.** | **UNITY BIOTECHNOLOGY, INC.** |
| By: | /s/ Craig R. Jalbert |
|  | Title: President, Secretary, and Director |

---

No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 in reliance on Rule 478 of the Securities Act of 1933, as amended.